{
  "study_type": "single-center real-world study",
  "location": "Sun Yat-sen Memorial Hospital, Sun Yat-sen University",
  "population": {
    "total_patients": 104,
    "conditions": "first-diagnosed idiopathic dilated cardiomyopathy (DCM)",
    "LVRR_occurrence": 47
  },
  "inclusion_criteria": [
    "LVDd >5.0 cm (female) or LVDd >5.5 cm (male)",
    "LVEF <45% and left ventricular shortening fraction <25%",
    "exclusion of other specific heart conditions"
  ],
  "exclusion_criteria": [
    "alcoholic cardiomyopathy, peripartum cardiomyopathy, and other acquired DCM",
    "history of heart failure treatment",
    "coronary heart disease, pulmonary heart disease, hypertensive heart disease, or pericardial disease",
    "severe systemic diseases or treatments affecting heart structure",
    "receiving cardiac resynchronization therapy or left ventricular assist device during follow-up"
  ],
  "experimental_groups": [
    "LVRR group",
    "non-LVRR group"
  ],
  "main_endpoints": [
    "absolute increase in LVEF from >10% to a final value >35%",
    "decrease in LVDd \u226510%"
  ],
  "followup_duration": "median time of 24 months, IQR 15\u201331",
  "data_collected": [
    "demographic characteristics",
    "physical signs",
    "comorbidities",
    "laboratory indicators",
    "electrocardiogram",
    "24-h dynamic electrocardiogram",
    "echocardiographic data",
    "medication"
  ],
  "techniques_used": [
    "Logistic regression",
    "Random Forest",
    "Extreme Gradient Boosting (XGBoost)"
  ],
  "model_evaluation": {
    "metrics": [
      "ROC curves",
      "AUC"
    ],
    "validation_type": "10-fold cross-validation"
  },
  "key_features_for_model": [
    "cystatin C",
    "right ventricular end-diastolic dimension",
    "high-density lipoprotein cholesterol (HDL-C)",
    "left atrial dimension",
    "left ventricular posterior wall dimension",
    "systolic blood pressure",
    "severe mitral regurgitation",
    "eGFR",
    "NYHA classification"
  ]
}